Shares of Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) have received a consensus rating of “Hold” from the six research firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $10.00.
Several research firms recently commented on EBS. JPMorgan Chase & Co. began coverage on Emergent Biosolutions in a research report on Friday, August 21st. They issued an “underweight” rating for the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Weiss Ratings raised Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Finally, Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th.
Check Out Our Latest Analysis on EBS
Insiders Place Their Bets
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Emergent Biosolutions in the second quarter worth about $39,525,000. Globeflex Capital L P bought a new position in shares of Emergent Biosolutions during the second quarter valued at approximately $2,022,000. Ancora Advisors LLC raised its holdings in shares of Emergent Biosolutions by 160.9% in the second quarter. Ancora Advisors LLC now owns 1,067,867 shares of the biopharmaceutical company’s stock worth $8,949,000 after buying an additional 658,600 shares during the period. Palisade Capital Management LP purchased a new stake in shares of Emergent Biosolutions in the second quarter worth approximately $4,316,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Emergent Biosolutions in the first quarter worth approximately $3,454,000. 78.40% of the stock is owned by hedge funds and other institutional investors.
Emergent Biosolutions Price Performance
EBS stock opened at $7.08 on Monday. Emergent Biosolutions has a 52 week low of $4.36 and a 52 week high of $14.06. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. The company has a fifty day simple moving average of $6.09 and a two-hundred day simple moving average of $7.47. The firm has a market capitalization of $362.94 million, a P/E ratio of -1.99 and a beta of 2.28.
Emergent Biosolutions (NYSE:EBS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. The business had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. Analysts anticipate that Emergent Biosolutions will post 0.13 earnings per share for the current fiscal year.
About Emergent Biosolutions
Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.
Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.
Featured Stories
- Five stocks we like better than Emergent Biosolutions
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
